Gilead has grown markedly in the 20 years since its inception. Our successful identification and development of drugs that attack HIV at different stages of the virus’s replication has established Gilead as a leader in this therapeutic category. Our resulting financial success has enabled us to fuel the development of new therapies for HIV and hepatitis, and to expand our product portfolio to include novel therapies to treat chronic respiratory and cardiopulmonary diseases. Our continued financial and corporate growth will not change who we are. We remain committed to developing and commercializing innovative therapeutics to treat life-threatening diseases worldwide. That is why we’re here at Gilead – for patients and their families.